脐带血扩增NK数据

NK细胞是人体先天免疫的核心组成部分，是肿瘤细胞免疫的基础。使用NK细胞治疗可以提高免疫力，在对抗实体瘤等癌症方面有很高功效与前景，使用中赢NK细胞扩增体系扩增NK细胞，成功率很高，稳定性高，能为有需要的人提供质量更高的服务，即使是脐带血也有较好成功率1.数据采集：采集脐带血NK细胞初始数据进行扩增培养； 2.进行滋养细胞扩增NK细胞培养：通过加液，添加滋养细胞进行扩增培养，整个过程进行12-14 天，不同时间都进行计数； 3.数据处理：分析最终得到的NK细胞数量，与初始量进行对比，得到扩增量与扩增倍数，并得到细胞纯度，扩增倍数大于1k即为扩增成功，统计多个样本数据，也可得到扩增成功率数据；4、数据应用：脐带血的扩增相对于外周血来说更为困难，使用脐带血进行扩增得到各项数据，证明了中赢滋养细胞体系高超的技术力，扩增成功率以及相关数据可以证明滋养细胞体系扩增NK细胞的优势，为客户和合作伙伴的选择提供数据支撑。

NK cells are a core component of human innate immunity and the foundation of anti-tumor cellular immunity. NK cell therapy can enhance immunity, demonstrating high efficacy and promising prospects in combating solid tumors and other cancers. The Zhongying NK cell expansion system features high success rate and excellent stability, enabling the provision of higher-quality services for those in need, and even achieves favorable success rates when processing umbilical cord blood samples.
1. Data Collection: Collect initial NK cell data from umbilical cord blood for expansion culture;
2. Feeder cell-mediated NK cell expansion culture: Conduct expansion culture by adding culture medium and feeder cells. The entire process lasts 12 to 14 days, with cell counting performed at different time points;
3. Data Processing: Analyze the final NK cell count, compare it with the initial quantity to obtain the expansion volume and fold change, and measure cell purity. An expansion fold greater than 1k is defined as successful expansion. Statistical analysis of multiple sample datasets can also generate expansion success rate data;
4. Data Application: Umbilical cord blood NK cell expansion is more challenging compared to peripheral blood. The various data obtained from umbilical cord blood expansion validate the superior technical capabilities of the Zhongying feeder cell system. The expansion success rate and related data confirm the advantages of the feeder cell system for NK cell expansion, providing solid data support for customer and partner decision-making.

搜集汇总

数据集介绍

特点

该数据集提供了脐带血中NK细胞的扩增数据，包含52条记录，涉及多个关键扩增指标，主要用于NK细胞治疗研究，已在区块链平台存证。